Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME
19 Dicembre 2019 - 5:45PM
Oxurion NV to Focus Clinical Development on Molecules Targeting
VEGF Independent Pathways for Treatment of DME
Oxurion NV to Focus Clinical Development
on Molecules Targeting VEGF Independent Pathways for Treatment of
DME
- Pipeline to focus on clinical development of THR-149 and
THR-687
- No further investment in the clinical development of
THR-317
- Commercialization of JETREA to be shifted to distributors/
licensees in marketed territories, patient access to be
maintained
Leuven, Belgium, 19 December 2019 –
17:45 CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company developing innovative back of the eye
treatments to preserve vision in patients with diabetic eye
disease, announces it is to focus its activities on the clinical
development of THR-149 and THR-687 as potential VEGF independent
treatments for Diabetic Macular Edema (DME). THR-149 is a novel
potent plasma kallikrein inhibitor while THR-687 is a Pan-RGD
integrin inhibitor, both of which have the potential to treat a
broad range of patients with diabetic eye disease.
Oxurion’s clinical pipeline now comprises:
• THR-149, which has shown positive topline
Phase 1 results for the treatment of DME. The Company plans to
conduct a Phase 2 clinical program, which is expected to start in
H1 2020.
• THR-687, which is in a Phase 1 clinical study
assessing it as a treatment for DME. Results from this study are
expected in early 2020.
Patrik De Haes, M.D., CEO of
Oxurion, said: “We believe that with THR-149 and THR-687
we have the opportunity to become a global leader in providing
retina physicians with novel VEGF independent treatment options for
patients with DME. There is clear need for novel medicines that act
via VEGF independent pathways, to address many of the limitations
of the VEGF inhibitors, the current standard of care for DME. It is
estimated that 40% of DME patients treated with anti-VEGF do not,
or sub optimally respond to anti-VEGF treatment.
Given the attractiveness of the VEGF independent
opportunity, and our confidence in our novel compounds’ ability to
address this clear unmet medical need, we have decided to make no
further investment in the development of THR-317. This reflects the
competitive nature of the VEGF market and the mixed Phase 2 results
with THR-317 which we released in August 2019. Results from the
on-going Mactel-1 study with THR-317 are expected to be presented
at a scientific conference in 2020.
The decisions we have announced today will simplify our
organizational structure, allowing us to focus our resources on
what we believe are two of the most exciting potential new
therapies for diabetic eye disease currently in the clinic.”
END
For further information please
contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer Hall Tel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing a pipeline of novel clinical
drug candidates acting on VEGF-independent pathways for the
treatment of diabetic eye disease, a leading cause of blindness in
people of working age worldwide.
Oxurion’s clinical pipeline comprises:
• THR-149, a plasma kallikrein inhibitor, that
has shown positive topline Phase 1 results for the treatment of
DME. The Company is currently preparing to conduct a Phase 2
clinical program, which is expected to start in H1 2020. THR-149
was developed in conjunction with Bicycle Therapeutics
• THR-687, a pan-RGD integrin inhibitor, that is
in a Phase 1 clinical study assessing it as a treatment for DME.
Results from this study are expected in early 2020. THR-687 is an
optimized compound derived from a broader library of integrin
inhibitors in-licensed from Galapagos.
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities law
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2023 a Apr 2024